LS CancerDiag Ltd is a company committed to reducing cancer mortality rates with a low-cost, comprehensive diagnostic method that detects an inherited cancer-causing deficiency prior to cancer formation. DiagMMR™, developed by LS CancerDiag Ltd, is a functional test that can be used for the diagnosis of MMR deficiency i.e. Lynch syndrome without prior knowledge of the individuals genetic background. Established in 2013 and based in Helsinki, LS CancerDiag Ltd is targeting to commercialize DiagMMR™ in 2017. For more information, please visit http://www.lscancerdiag.com/.